ANTIMICROBIAL RESISTANCE - MANAGING THE RISKS & IDENTIFYING THE OPPORTUNITIES FOR GLOBAL INVESTMENT
21 November 2019
EBRD, Boardroom
Programme
0830
REGISTRATION AND REFRESHMENTS
0900
Introduction and welcome
Dr Alistair Clark, Managing Director, Environment & Sustainability Dept., EBRD
SESSION ONE: Keynote lecture
Chair: Dr Alistair Clark, EBRD
0910
AMR – somebody else’s problem?
Dame Sally Davies, UK Government’s Special Envoy on AMR
SESSION TWO: Setting the scene
Chair: Professor Philip Howard, Leeds Teaching Hospitals and University of Leeds, BSAC President
0940
Healthy Nations, Sustainable Economies: How Innovation Can Better Ensure Health for All
Professor David Heymann, Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine
1010
The cost of inaction – what level of investment is required and where should it come from?
Lord Jim O'Neill, Chairman, Chatham House
1040
The education and implementation gap: why large-scale private investment matters
Professor Dilip Nathwani OBE, Director of the Academic Health Science Partnership (AHSP) in Tayside, Honorary Professor of Infection, Ninewells Hospital and Medical School
1110
Role of industry and the private sector in advancing the cause of AMR
Mr Gary Cohen, Executive Vice President, Global Health and President, BD Foundation
1140
REFRESHMENTS AND NETWORKING
SESSION THREE: Global governance framework for AMR
1210
Discussion: How can the global governance framework for AMR accelerate way in which we address AMR?
Dr Elizabeth Tayler, Antimicrobial Resistance Tripartite Joint Secretariat, World Health Organization
SESSION FOUR: Roundtable discussion - The Investors’ perspective on creating an investment proposition for AMR
Chair: Dr Elizabeth Tayler, Antimicrobial Resistance Tripartite Joint Secretariat, World Health Organization
1250
Creating investment propositions for AMR – EBRD’s international response
Ms Nobuko Ichikawa, Senior Environmental Advisor, EBRD
1300
Panel discussion
Panel members:
Dr Subashini Mm, Associate Medical Director, Aviva
Dr Emma Berntman, Manager, Hermes Investment Management
Ms Aarti Ramachandran, Head of Research & Engagements, FAIRR Initiative
Dr Damiano de Felice, Director of Strategy, Access to Medicine Foundation
Dr Subashini Mm, Associate Medical Director, Aviva
Dr Emma Berntman, Manager, Hermes Investment Management
Ms Aarti Ramachandran, Head of Research & Engagements, FAIRR Initiative
Dr Damiano de Felice, Director of Strategy, Access to Medicine Foundation
1340
LUNCH AND NETWORKING
SESSION FIVE: Roundtable – Industries’ perspective
Chair: Professor Peter Borriello, Chief Executive Officer, Veterinary Medicines Directorate
1430
Panel Discussion
Panel members:
Dr Kitty Healey, Head of Antimicrobial Resistance, Veterinary Medicines Directorate
Mrs Jo Raven, Engagement Manager, FAIRR Initiative
Professor Laura Piddock, Director of Scientific Affairs, GARDP
Ms Catherine McLaughlin, RUMA Deputy Chairman, RUMA UK
James Anderson, Head, Government Corporate Affairs, GSK
Dr Damiano de Felice, Director of Strategy, Access to Medicine Foundation
Dr Kitty Healey, Head of Antimicrobial Resistance, Veterinary Medicines Directorate
Mrs Jo Raven, Engagement Manager, FAIRR Initiative
Professor Laura Piddock, Director of Scientific Affairs, GARDP
Ms Catherine McLaughlin, RUMA Deputy Chairman, RUMA UK
James Anderson, Head, Government Corporate Affairs, GSK
Dr Damiano de Felice, Director of Strategy, Access to Medicine Foundation
SESSION SIX: Protecting the shareholder bottom line through investment
Chair: Professor Mark Woolhouse, Professor ID Epidemiology, University of Edinburgh & Matt Crossman, Stewardship Director, Rathbones
1515
The One Health agenda and an overview of Environmental, social and corporate governance
Introduction by Chairs
1525
Panel-led discussion: Creating an investment community for AMR
Panel members:
Dame Sally Davies, UK Special Envoy on AMR, UK Government
Professor Dilip Nathwani OBE, Director of the Academic Health Science Partnership (AHSP) in Tayside, Honorary Professor of Infection, Ninewells Hospital and Medical School
Professor Peter Boriello, Chief Executive Officer, Veterinary Medicines Directorate
Dr Alistair Clark, Managing Director, Environment & Sustainability Dept., EBRD
Mr Daniel Berman, Head, Global Health, Nesta Challenges
Dame Sally Davies, UK Special Envoy on AMR, UK Government
Professor Dilip Nathwani OBE, Director of the Academic Health Science Partnership (AHSP) in Tayside, Honorary Professor of Infection, Ninewells Hospital and Medical School
Professor Peter Boriello, Chief Executive Officer, Veterinary Medicines Directorate
Dr Alistair Clark, Managing Director, Environment & Sustainability Dept., EBRD
Mr Daniel Berman, Head, Global Health, Nesta Challenges
WRAP UP AND CLOSING REMARKS
1600
AMR policy within your organisation: it’s about action as much as money
Dr Alistair Clark, Managing Director, Environment & Sustainability Dept., EBRD
European Bank for Reconstruction and Development (EBRD)
We strengthen developing economies by making them more competitive, well-governed, green, inclusive, resilient and integrated
We invest in projects, most of them in the private sector, work on policy reform and provide technical advice, all of which powers sustainable growth
